Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease

V Panwar, A Singh, M Bhatt, RK Tonk… - Signal transduction and …, 2023 - nature.com
The mammalian target of rapamycin (mTOR) is a protein kinase that controls cellular
metabolism, catabolism, immune responses, autophagy, survival, proliferation, and …

A comprehensive review on MAPK: a promising therapeutic target in cancer

C Braicu, M Buse, C Busuioc, R Drula, D Gulei… - Cancers, 2019 - mdpi.com
The mitogen-activated protein kinase (MAPK) pathway is an important bridge in the switch
from extracellular signals to intracellular responses. Alterations of signaling cascades are …

The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling

BY Shorning, MS Dass, MJ Smalley… - International journal of …, 2020 - mdpi.com
Oncogenic activation of the phosphatidylinositol-3-kinase (PI3K), protein kinase B
(PKB/AKT), and mammalian target of rapamycin (mTOR) pathway is a frequent event in …

mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy

T Tian, X Li, J Zhang - International journal of molecular sciences, 2019 - mdpi.com
The mammalian or mechanistic target of rapamycin (mTOR) pathway plays a crucial role in
regulation of cell survival, metabolism, growth and protein synthesis in response to upstream …

Wnt and PI3K/Akt/mTOR survival pathways as therapeutic targets in glioblastoma

A Barzegar Behrooz, Z Talaie, F Jusheghani… - International journal of …, 2022 - mdpi.com
Glioblastoma (GBM) is a devastating type of brain tumor, and current therapeutic treatments,
including surgery, chemotherapy, and radiation, are palliative at best. The design of effective …

Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer

M Mortazavi, F Moosavi, M Martini, E Giovannetti… - Critical reviews in …, 2022 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) has one of the worst prognoses among all
malignancies. PI3K/AKT/mTOR signaling pathway, a main downstream effector of KRAS is …

PI3K-AKT-mTOR and NFκB pathways in ovarian cancer: implications for targeted therapeutics

A Ghoneum, N Said - Cancers, 2019 - mdpi.com
Ovarian cancer is the most lethal gynecologic malignancy in the United States, with an
estimated 22,530 new cases and 13,980 deaths in 2019. Recent studies have indicated that …

[HTML][HTML] Adapt and conquer: Metabolic flexibility in cancer growth, invasion and evasion

P Kreuzaler, Y Panina, J Segal, M Yuneva - Molecular metabolism, 2020 - Elsevier
Background It has been known for close to a century that, on average, tumors have a
metabolism that is different from those found in healthy tissues. Typically, tumors show a …

From carcinogenesis to therapeutic avenues: lncRNAs and mTOR crosstalk in lung cancer

MS Hussain, ASA Altamimi, M Afzal, I Kazmi… - … -Research and Practice, 2024 - Elsevier
Long non-coding RNAs (lncRNAs) have been demonstrated to have a crucial function in the
modulation of the activity of genes, impacting a variety of homeostatic processes involving …

mTOR: a cellular regulator interface in health and disease

F Boutouja, CM Stiehm, HW Platta - Cells, 2019 - mdpi.com
The mechanistic target of Rapamycin (mTOR) is a ubiquitously-conserved serine/threonine
kinase, which has a central function in integrating growth signals and orchestrating their …